{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:35:45Z","timestamp":1783625745822,"version":"3.55.0"},"reference-count":61,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Inv(3)(q21q26)\/t(3;3)(q21;q26.2) is the most common form of genetic abnormality of the so-called 3q21q26 syndrome. Myeloid neoplasms with 3q21q26 aberrancies include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blast crisis of myeloproliferative neoplasms. Recent advances on myeloid neoplasms with inv(3)\/t(3;3) with regard to clinicopathologic features and novel molecular or genomic findings warrant a comprehensive review on this topic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To review the clinicopathologic features and molecular as well as genomic alterations in myeloid neoplasms with inv(3)\/t(3;3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources.\u2014<\/jats:title>\n                    <jats:p>The data came from published articles in English-language literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>At the clinicopathologic front, recent studies on MDS with inv(3)\/t(3;3) have highlighted their overlapping clinicopathologic features with and similar overall survival to that of inv(3)\/t(3;3)-harboring AML regardless of the percentage of myeloid blasts. On the molecular front, AML and MDS with inv(3)\/t(3;3) exhibit gene mutations, which affect the RAS\/receptor tyrosine kinase pathway. Furthermore, functional genomic studies using genomic editing and genome engineering have shown that the reallocation of the GATA2 distal hematopoietic enhancer to the proximity of the promoter of ectopic virus integration site 1 (EVI1) without the formation of a new oncogenic fusion transcript is the molecular mechanism underlying these inv(3)\/t(3;3) myeloid neoplasms. Although the AML and MDS with inv(3)\/t(3;3) are listed as a separate category of myeloid malignancies in the 2008 World Health Organization classification, the overlapping clinicopathologic features, similar overall survival, and identical patterns at the molecular and genomic levels between AML and MDS patients with inv(3)\/t(3;3) may collectively favor a unification of AML and MDS with inv(3)\/t(3;3) as AML or myeloid neoplasms with inv(3)\/t(3;3) regardless of the blast count.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2016-0059-ra","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T09:46:30Z","timestamp":1473932790000},"page":"1404-1410","source":"Crossref","is-referenced-by-count":11,"title":["The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)\/t(3;3)(q21;q26.2)"],"prefix":"10.5858","volume":"140","author":[{"given":"Huan-You","family":"Wang","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of California San Diego Health System, La Jolla (Dr Wang); and the Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento (Dr Rashidi)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman H.","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b01","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-4608(79)90008-6","article-title":"Acute myelogenous leukemia and thrombocythemia associated with an abnormality of chromosome No. 3","volume":"1","author":"Sweet","year":"1979","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2020081222343799000_i1543-2165-140-12-1404-b02","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood.V60.3.613.613","article-title":"Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a \u201cnew\u201d inversion anomaly and a further case of homologous translocation","volume":"60","author":"Bernstein","year":"1982","journal-title":"Blood"},{"issue":"3","key":"2020081222343799000_i1543-2165-140-12-1404-b03","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/1097-0142(19850201)55:3<535::AID-CNCR2820550311>3.0.CO;2-4","article-title":"San Roman C, Mayaya M, Larana JG. Clinical correlation of the 3q21;3q26 cytogenetic anomaly: a leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy","volume":"55","author":"Pintado","year":"1985","journal-title":"Cancer"},{"issue":"6","key":"2020081222343799000_i1543-2165-140-12-1404-b04","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood.V66.6.1362.1362","article-title":"Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute non-lymphocytic leukemia","volume":"66","author":"Bitter","year":"1985","journal-title":"Blood"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b05","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0165-4608(92)90208-P","article-title":"Three new cases of chromosome 3 rearrangements in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome","volume":"59","author":"Bellomo","year":"1992","journal-title":"Cancer Genet Cytogenet"},{"issue":"24","key":"2020081222343799000_i1543-2165-140-12-1404-b06","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.2010.29.2771","article-title":"Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)\/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia","volume":"28","author":"Lugthart","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020081222343799000_i1543-2165-140-12-1404-b07","first-page":"690","article-title":"3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: biological and clinical features","volume":"84","author":"Testoni","year":"1999","journal-title":"Haematologica"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b08","first-page":"350","article-title":"Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blasts crisis","volume":"4","author":"Lee","year":"1990","journal-title":"Leukemia"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b09","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cancergencyto.2007.12.016","article-title":"Association of inv(3)(q21q26) with essential thrombocythemia in transformation","volume":"184","author":"Villal\u00f3n","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1309\/AJCP48AJDCKTHUXC","article-title":"Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia","volume":"136","author":"Cui","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"2020081222343799000_i1543-2165-140-12-1404-b11","article-title":"Myelodysplastic syndromes\/neoplasms, overview","author":"Brunning","year":"2008","journal-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2013.096420","article-title":"Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study","volume":"99","author":"Rogers","year":"2014","journal-title":"Haematologica"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.leukres.2009.08.029","article-title":"Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)\/t(3;3)(q21;q26.2)","volume":"34","author":"Medeiros","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0165-4608(96)00293-2","article-title":"Chromosomal abnormality inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in hematopoietic malignancies","volume":"96","author":"Shi","year":"1997","journal-title":"Cancer Genet Cytogenet"},{"issue":"3","key":"2020081222343799000_i1543-2165-140-12-1404-b15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/modpathol.2010.210","article-title":"De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification","volume":"24","author":"Sun","year":"2011","journal-title":"Mod Pathol"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b16","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/leu.2011.5","article-title":"The inv(3)(q21q26)\/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML","volume":"25","author":"Haferlach","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2020081222343799000_i1543-2165-140-12-1404-b17","first-page":"356","article-title":"3q aberration and monosomy 7 in ANLL presenting with high platelet count and diabetes insipidus","volume":"79","author":"La Starza","year":"1994","journal-title":"Haematologica"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0165-4608(02)00521-6","article-title":"Central diabetes insipidus and inv(3)(q21q26) and monosomy 7 in acute myeloid leukemia","volume":"136","author":"Keung","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0609.2001.00346.x","article-title":"Diabetes insipidus revealing acute myelogenous leukemia with a high platelet count, monosomy 7 and abnormalities of chromosome 3: a new entity?","volume":"66","author":"Lavabre-Bertrand","year":"2001","journal-title":"Eur J Haematol"},{"key":"2020081222343799000_i1543-2165-140-12-1404-b20","article-title":"Acute myeloid leukemia with recurrent genetic abnormalities","author":"Arber","year":"2008","journal-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2014-07-591461","article-title":"Mutational spectrum of myeloid malignancies with inv(3)\/t(3;3) reveals a predominant involvement of RAS\/RTK signaling pathways","volume":"125","author":"Gr\u00f6schel","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020081222343799000_i1543-2165-140-12-1404-b22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(88)91175-0","article-title":"Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines","volume":"54","author":"Morishita","year":"1988","journal-title":"Cell"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1128\/MCB.8.1.301","article-title":"Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors","volume":"8","author":"Mucenski","year":"1988","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2020081222343799000_i1543-2165-140-12-1404-b24","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1073\/pnas.89.9.3937","article-title":"Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26","volume":"89","author":"Morishita","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12185-010-0618-5","article-title":"Evi-1 as a critical regulator of leukemic cells","volume":"91","author":"Goyama","year":"2010","journal-title":"Int J Hematol"},{"issue":"7","key":"2020081222343799000_i1543-2165-140-12-1404-b26","first-page":"963","article-title":"Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts","volume":"5","author":"Morishita","year":"1990","journal-title":"Oncogene"},{"issue":"6","key":"2020081222343799000_i1543-2165-140-12-1404-b27","first-page":"1575","article-title":"The carboxyl domain of zinc finger s of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG","volume":"9","author":"Funabiki","year":"1994","journal-title":"Oncogene"},{"issue":"11","key":"2020081222343799000_i1543-2165-140-12-1404-b28","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.emboj.7600679","article-title":"Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression","volume":"24","author":"Yuasa","year":"2005","journal-title":"EMBO J"},{"issue":"10","key":"2020081222343799000_i1543-2165-140-12-1404-b29","first-page":"1961","article-title":"EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC","volume":"10","author":"Morishita","year":"1995","journal-title":"Oncogene"},{"issue":"39","key":"2020081222343799000_i1543-2165-140-12-1404-b30","doi-asserted-by":"crossref","first-page":"24020","DOI":"10.1016\/S0021-9258(19)51041-9","article-title":"Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain","volume":"269","author":"Tanaka","year":"1994","journal-title":"J Biol Chem"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b31","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-06-3962","article-title":"Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis","volume":"67","author":"Senyuk","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"2020081222343799000_i1543-2165-140-12-1404-b32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.onc.1200864","article-title":"The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation","volume":"14","author":"Bartholomew","year":"1997","journal-title":"Oncogene"},{"issue":"7","key":"2020081222343799000_i1543-2165-140-12-1404-b33","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1349-7006.2008.00842.x","article-title":"Evi-1 promotes para-aortic splanchnopleural hematopoiesis through up-regulation of GATA-2 and repression of TGF-b signaling","volume":"99","author":"Sato","year":"2008","journal-title":"Cancer Sci"},{"issue":"3","key":"2020081222343799000_i1543-2165-140-12-1404-b34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.leu.2400584","article-title":"The leukemia-associated gene MDS\/EVI1 is a new type of GATA-binding transactivator","volume":"11","author":"Soderholm","year":"1997","journal-title":"Leukemia"},{"issue":"9","key":"2020081222343799000_i1543-2165-140-12-1404-b35","first-page":"1419","article-title":"The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes","volume":"5","author":"Morishita","year":"1990","journal-title":"Oncogene"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b36","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1084\/jem.20110447","article-title":"Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity","volume":"208","author":"Kataoka","year":"2011","journal-title":"J Exp Med"},{"issue":"4","key":"2020081222343799000_i1543-2165-140-12-1404-b37","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1073\/pnas.93.4.1642","article-title":"Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family","volume":"93","author":"Fears","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020081222343799000_i1543-2165-140-12-1404-b38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.gene.2005.04.032","article-title":"Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5\u2032-ends","volume":"356","author":"Aytekin","year":"2005","journal-title":"Gene"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","article-title":"Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells","volume":"3","author":"Goyama","year":"2008","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/gcc.10144","article-title":"Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1\/EVI1, in patients with myeloid leukemia","volume":"36","author":"Vinatzer","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b41","doi-asserted-by":"crossref","first-page":"e89397","DOI":"10.1371\/journal.pone.0089397","article-title":"Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects","volume":"9","author":"Bard-Chapeau","year":"2014","journal-title":"PLoS One"},{"issue":"1\u20132","key":"2020081222343799000_i1543-2165-140-12-1404-b42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0925-4773(97)00057-9","article-title":"The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development","volume":"65","author":"Hoyt","year":"1997","journal-title":"Mech Dev"},{"issue":"9","key":"2020081222343799000_i1543-2165-140-12-1404-b43","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1073\/pnas.91.9.4004","article-title":"Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations","volume":"91","author":"Nucifora","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2020081222343799000_i1543-2165-140-12-1404-b44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1006\/bbrc.1998.9588","article-title":"Comparative expression analysis of the antagonistic transcription factors EVI1 and MDS1-EVI1 in murine tissues and during in vitro hematopoietic differentiation","volume":"252","author":"Wimmer","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2020081222343799000_i1543-2165-140-12-1404-b45","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated","volume":"111","author":"Lugthart","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b46","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020081222343799000_i1543-2165-140-12-1404-b47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/gcc.20532","article-title":"Expression and prognostic significance of different mRNA 5\u2032-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1\/EVI1 overexpression both predict short remission duration","volume":"47","author":"Hass","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/gcc.21992","article-title":"Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases","volume":"51","author":"Haferlach","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2020081222343799000_i1543-2165-140-12-1404-b49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.2011.41.5505","article-title":"Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON\/SAKK Cooperative Group","volume":"31","author":"Gr\u00f6schel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b50","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.leukres.2015.09.021","article-title":"Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: a study by the ALFA Group","volume":"39","author":"Smol","year":"2015","journal-title":"Leuk Res"},{"issue":"8","key":"2020081222343799000_i1543-2165-140-12-1404-b51","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood.V84.8.2681.2681","article-title":"Identification of a breakpoint cluster region 3\u2032 of the Ribophorin 1 gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemia with inv(3)(q21q26)","volume":"84","author":"Suzukawa","year":"1994","journal-title":"Blood"},{"issue":"12","key":"2020081222343799000_i1543-2165-140-12-1404-b52","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/sj.leu.2400880","article-title":"The EVI1 gene in myeloid leukemia","volume":"11","author":"Nucifora","year":"1997","journal-title":"Leukemia"},{"issue":"11","key":"2020081222343799000_i1543-2165-140-12-1404-b53","first-page":"1221","article-title":"Association of 3q21q26 syndrome with different RPN1\/EVI1 fusion transcripts","volume":"88","author":"Martinelli","year":"2003","journal-title":"Haematologica"},{"issue":"18","key":"2020081222343799000_i1543-2165-140-12-1404-b54","first-page":"3911","article-title":"Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site 1 in leukemia","volume":"57","author":"Pekarsky","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cancergencyto.2006.05.007","article-title":"Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements","volume":"170","author":"Madrigal","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"2020081222343799000_i1543-2165-140-12-1404-b56","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-2141.2007.06505.x","article-title":"An interphase fluorescence in situ hybridization assay for the detection of 3q26.2\/EVI1 rearrangements in myeloid malignancies","volume":"136","author":"Bobadilla","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"2020081222343799000_i1543-2165-140-12-1404-b57","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ajh.21746","article-title":"Development of a dual-color, double fusion FISH assay to detect RPN1\/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia","volume":"85","author":"Shearer","year":"2010","journal-title":"Am J Hematol"},{"issue":"4","key":"2020081222343799000_i1543-2165-140-12-1404-b58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2014.03.031","article-title":"Genomic dark matters shed light on EVI1-driven leukemia","volume":"25","author":"Koche","year":"2014","journal-title":"Cancer Cell"},{"issue":"2","key":"2020081222343799000_i1543-2165-140-12-1404-b59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"issue":"4","key":"2020081222343799000_i1543-2165-140-12-1404-b60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","article-title":"A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression","volume":"25","author":"Yamazaki","year":"2014","journal-title":"Cancer Cell"},{"issue":"48","key":"2020081222343799000_i1543-2165-140-12-1404-b61","doi-asserted-by":"crossref","first-page":"10431","DOI":"10.1021\/bi200962u","article-title":"Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide","volume":"50","author":"Zhang","year":"2011","journal-title":"Biochemistry"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/12\/1404\/1615356\/arpa_2016-0059-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/140\/12\/1404\/1615356\/arpa_2016-0059-ra.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:10Z","timestamp":1764790510000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/140\/12\/article-p1404.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,15]]},"references-count":61,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,9,15]]},"published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2016-0059-ra","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,15]]}}}